Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Finished Goods: 2023-2024

Historic Finished Goods for Iovance Biotherapeutics (IOVA) over the last 2 years, with Dec 2024 value amounting to $15.0 million.

  • Iovance Biotherapeutics' Finished Goods rose 153.30% to $15.5 million in Q1 2025 from the same period last year, while for Mar 2025 it was $15.5 million, marking a year-over-year increase of 153.30%. This contributed to the annual value of $15.0 million for FY2024, which is 224.72% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Finished Goods stood at $15.0 million for FY2024, which was up 224.72% from $4.6 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' Finished Goods ranged from a high of $15.0 million in FY2024 and a low of $4.6 million during FY2023.
  • For the 2-year period, Iovance Biotherapeutics' Finished Goods averaged around $9.8 million, with its median value being $9.8 million (2023).
  • Data for Iovance Biotherapeutics' Finished Goods shows a peak YoY skyrocketed of 224.72% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Iovance Biotherapeutics' Finished Goods stood at $4.6 million in 2023, then skyrocketed by 224.72% to $15.0 million in 2024.